Oragenics Inc., a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced its participation at the SCOPE Summit 2026, the 17th annual Summit for Clinical Ops Executives organized by the Cambridge Healthtech Institute. The company plans to engage with leaders across biopharma, clinical research, regulatory affairs, and clinical technology as it advances its proprietary intranasal delivery platform and prepares for a Phase 2a clinical trial in Australia of ONP-002, its therapeutic candidate for concussion and mild traumatic brain injury.
The development of ONP-002 represents a critical effort to address areas with significant unmet medical need and no FDA-approved treatments. Concussion and mild traumatic brain injury affect millions globally, yet current management focuses primarily on symptom monitoring and rest rather than targeted therapeutic intervention. Oragenics’ approach utilizes a proprietary intranasal delivery system designed to transport therapeutics directly to the brain, potentially offering a novel mechanism of action for neurological conditions.
The company’s participation in the SCOPE Summit 2026, being held February 2–5, 2026, in Orlando, Florida, provides a strategic opportunity to collaborate with industry experts as it advances toward clinical trials. Following the planned Australian Phase 2a trials, Oragenics intends to proceed with U.S. Phase 2b trials for ONP-002. The company’s broader intranasal delivery platform has potential applications across multiple neurological conditions beyond concussion, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
This development matters because it represents one of the few advanced therapeutic approaches specifically targeting the underlying pathophysiology of concussion rather than merely managing symptoms. The absence of FDA-approved treatments for concussion creates both a significant medical gap and a substantial market opportunity. Successful development of ONP-002 could establish a new treatment paradigm for traumatic brain injury patients and validate Oragenics’ intranasal delivery platform for broader neurological applications.
The company maintains a newsroom at https://ibn.fm/OGEN where updates relating to OGEN are available. Additional information about Oragenics can be found at https://www.oragenics.com. The SCOPE Summit participation represents a strategic step in the company’s clinical development pathway as it works to translate its intranasal delivery technology into meaningful patient benefits for neurological disorders that currently lack effective therapeutic options.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oragenics Advances Concussion Treatment Development with SCOPE Summit Participation Ahead of Australian Phase 2a Trial.